Literature DB >> 26373373

Cooperative development of antimicrobials: looking back to look ahead.

Carl Nathan1.   

Abstract

As foundations and governments mobilize to tackle antimicrobial resistance (AMR), several experiments in academic-industrial collaboration have emerged. Here, I examine two historical precedents, the Penicillin Project and the Malaria Project of the Second World War, and two contemporary examples, the Tuberculosis Drug Accelerator programme and the Tres Cantos Open Lab. These and related experiments suggest that different strategies can be effective in managing academic-industrial collaborations, and that such joint projects can prosper in both multisite and single-site forms, depending on the specific challenges and goals of each project. The success of these strategies and the crisis of AMR warrant additional investment in similar projects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26373373     DOI: 10.1038/nrmicro3523

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  20 in total

Review 1.  Why is big Pharma getting out of antibacterial drug discovery?

Authors:  Steven J Projan
Journal:  Curr Opin Microbiol       Date:  2003-10       Impact factor: 7.934

2.  Pitfalls in a discovery: the chronicle of chloroquine.

Authors:  G R COATNEY
Journal:  Am J Trop Med Hyg       Date:  1963-03       Impact factor: 2.345

3.  MMV: New Medicines for Malaria Venture.

Authors: 
Journal:  TDR News       Date:  1999-02

4.  Stoking the antibiotic pipeline.

Authors:  Chantal M Morel; Elias Mossialos
Journal:  BMJ       Date:  2010-05-18

Review 5.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

6.  Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.

Authors:  Seamus O'Brien
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  TRANSLOCATION project: how to get good drugs into bad bugs.

Authors:  Robert A Stavenger; Mathias Winterhalter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

8.  Spiroindolones, a potent compound class for the treatment of malaria.

Authors:  Matthias Rottmann; Case McNamara; Bryan K S Yeung; Marcus C S Lee; Bin Zou; Bruce Russell; Patrick Seitz; David M Plouffe; Neekesh V Dharia; Jocelyn Tan; Steven B Cohen; Kathryn R Spencer; Gonzalo E González-Páez; Suresh B Lakshminarayana; Anne Goh; Rossarin Suwanarusk; Timothy Jegla; Esther K Schmitt; Hans-Peter Beck; Reto Brun; Francois Nosten; Laurent Renia; Veronique Dartois; Thomas H Keller; David A Fidock; Elizabeth A Winzeler; Thierry T Diagana
Journal:  Science       Date:  2010-09-03       Impact factor: 47.728

Review 9.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

Review 10.  Fresh approaches to anti-infective therapies.

Authors:  Carl Nathan
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

View more
  12 in total

1.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

2.  Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.

Authors:  Maaike Everts; Mark J Suto; George R Painter; Richard J Whitley
Journal:  Future Virol       Date:  2016-02-29       Impact factor: 1.831

Review 3.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

Review 4.  Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.

Authors:  Robert S Jansen; Kyu Y Rhee
Journal:  Trends Pharmacol Sci       Date:  2017-02-03       Impact factor: 14.819

Review 5.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

Review 6.  Collaborative public-private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012-2016.

Authors:  Peter W Shelby; Maria Paola Lia; Amy Israel
Journal:  J Healthc Leadersh       Date:  2017-06-06

Review 7.  Kunkel Lecture: Fundamental immunodeficiency and its correction.

Authors:  Carl Nathan
Journal:  J Exp Med       Date:  2017-07-12       Impact factor: 14.307

Review 8.  Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Authors:  John Billington; Isabelle Deschamps; Stanley C Erck; Julie L Gerberding; Emmanuel Hanon; Sabrina Ivol; John W Shiver; Julia A Spencer; Johan Van Hoof
Journal:  Health Secur       Date:  2020-04-29

9.  Honing the Priorities and Making the Investment Case for Global Health.

Authors:  Trevor Mundel
Journal:  PLoS Biol       Date:  2016-03-02       Impact factor: 8.029

10.  Repurposing clinically approved cephalosporins for tuberculosis therapy.

Authors:  Santiago Ramón-García; Rubén González Del Río; Angel Santos Villarejo; Gaye D Sweet; Fraser Cunningham; David Barros; Lluís Ballell; Alfonso Mendoza-Losana; Santiago Ferrer-Bazaga; Charles J Thompson
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.